SCHEMBL4896467

SCHEMBL4896467

O=C(NCc1ccc2nsnc2c1)c1ccc(-c2cccc(Cl)c2)o1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.62
KDM4E B2RXH2 6/20 0.62
MAPT P10636 5/20 0.62
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
POLB P06746 2/20 0.62
CYP1A2 P05177 2/20 0.62
CYP2C19 P33261 2/20 0.62
SAE1 Q9UBE0 1/20 0.62
UBA2 Q9UBT2 1/20 0.62
RAB9A P51151 3/20 0.61
MGAM O43451 1/20 0.52
GAA P10253 1/20 0.52
SI P14410 1/20 0.52
MGAM2 Q2M2H8 1/20 0.52
S1PR4 O95977 1/20 0.51
HTT P42858 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
TP53 P04637 2/20 0.48
LMNA P02545 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4896955 0.81 ALDH1A1 (0.67) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL4896863 0.81 ALDH1A1 (0.69) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL4897438 0.79 ALDH1A1 (0.64) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL30715120 0.76 ALDH1A1 (0.65) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL29195048 0.76 ALDH1A1 (0.65) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL4895912 0.76 ALDH1A1 (0.65) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL20764223 0.74 ALDH1A1 (0.60) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL4894551 0.73 ALDH1A1 (0.68) ALDH1A1KDM4EMAPTPOLBRAB9A
SCHEMBL4894925 0.73 MAPK1 (0.54) ALDH1A1KDM4EMAPTPOLBRAB9A
SCHEMBL4893613 0.72 ALDH1A1 (0.55) ALDH1A1KDM4EMAPTPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090882-A1 Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans MERCK PATENT GMBH (DE) 2008-04-17 US claimed
US-8815924-B2 Heterocyclic carbonyl compounds MERCK PATENT GMBH (DE) 2014-08-26 US disclosed
US-20080090882-A1 Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans MERCK PATENT GMBH (DE) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090882-A1 Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans SGK1, SGK2, SGK3 ALDH1A1 3961/4885KDM4E 2561/4885MAPT 3797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.